Banco Bilbao Vizcaya Argentaria S.A. Cuts Stock Position in DexCom, Inc. $DXCM

Banco Bilbao Vizcaya Argentaria S.A. trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,763 shares of the medical device company’s stock after selling 1,563 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in DexCom were worth $764,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. SWS Partners purchased a new position in DexCom during the 2nd quarter valued at about $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in DexCom in the 2nd quarter worth approximately $393,000. Jennison Associates LLC grew its position in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of DexCom by 4.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after buying an additional 6,800 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of DexCom by 85.7% during the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after acquiring an additional 557,576 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares in the company, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 9,999 shares of company stock valued at $619,391. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $58.49 on Tuesday. The company has a 50 day simple moving average of $66.86 and a two-hundred day simple moving average of $77.17. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The company has a market capitalization of $22.81 billion, a price-to-earnings ratio of 40.62, a P/E/G ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DXCM shares. Barclays set a $80.00 price target on shares of DexCom and gave the company an “equal weight” rating in a report on Monday, November 3rd. Citigroup dropped their target price on shares of DexCom from $85.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Stifel Nicolaus began coverage on shares of DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price on the stock. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Finally, Robert W. Baird set a $82.00 price objective on shares of DexCom in a report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.